DOP088IBD-PERFECT: Development of a performance evaluation and review framework to improve clinical care in Inflammatory Bowel Disease

Abstract Background Inflammatory bowel disease (IBD) care varies widely, but differences are often not visible without structured measurement and benchmarking. Broader healthcare experience shows that clinicians and institutions often assume they provide high-quality care, yet transparent reporting frequently reveals substantial variation (1, 2). Clinical Quality Registries (CQRs) provide a framework for such measurement, while integrating registry data into digital dashboards enables timely feedback and visualisation of key performance indicators (KPIs) to support quality improvement (3, 4). We aimed to develop and implement IBD-PERFECT, a multicentre, data-driven dashboard that benchmarks IBD care and supports continuous quality improvement. Methods IBD-PERFECT was co-designed by clinicians, researchers, and members of the Crohn’s Colitis Cure (CCCure) organisation. The platform links data from Crohn’s Colitis Care (CCCare), an IBD-specific electronic medical record used across Australasia, with Microsoft Power BI dashboards hosted in Azure and supported by Stratos Technology Partners. Data collected prospectively during routine care are de-identified and flow into a CQR. Dashboards display aggregate and site-level data with tiered access (public, institutional, and internal). Six initial KPIs were selected: smoking, steroid use, opiate use, clinically active disease, anaemia, and colorectal cancer surveillance eligibility. Each KPI is paired with a data completion metric for documentation quality. Security, privacy, and risk management protocols were established to safeguard patient confidentiality, implementing role-based access controls that restrict data visibility to authorised site personnel only. Results IBD-PERFECT was launched during Australian Gastroenterology Week (22 September 2025). At launch, the registry contained 16,925 patient records from 20 centres; 10,134 (59.8%) comprised the clinical cohort (≥ 1 clinical assessment), and 6,676 (39.4%) were active (assessed within 14 months). The dashboard displays simultaneous aggregate and site-level data and received over 300 visits within the first 2 months. Early benchmarking showed that 29% of the clinical cohort were overdue for review, identifying a target for follow-up and care continuity. KPIs are presented as absolute values and temporal trends, accompanied by completion metrics to support local audit and improvement cycles. Conclusion IBD-PERFECT is a clinician-led platform supporting benchmarking and feedback across centres. Future work will expand indicators, enhance usability, and incorporate site-level surveys to capture structural and process measures alongside outcomes for comprehensive benchmarking of care quality and resourcing. References: 1.Gawande A. The Bell Curve. The New Yorker. 2004. 2.Aitken L, et al. Medical colleges’ obligation to ensure participation in clinical quality registries. Med J Aust. 2025. 3.Coiera E, et al. Clinical and economic impact of digital dashboards on hospital inpatient care: a systematic review. JAMIA Open. 2025. 4.Ibrahim AM, et al. Transparency, public reporting and a culture of change to quality and safety in cardiac surgery. Ann Thorac Surg. 2022. Conflict of interest: Caquilpan, Victor: No conflict of interest Wu, Rodger: No conflict of interest Deschenes, Renee: No conflict of interest Wilson, William: No conflict of interest Su, Wai Kin: No conflict of interest Palmer, Lyle J: No conflict of interest Petch, Bill: No conflict of interest Jackman, Greg: No conflict of interest Langford, Simon: No conflict of interest Connor, Susan Jane: Grant: Research Support: Abbvie, Agency for Clinical Innovation, Amgen, BMS, Chiesi, Celltrion, DrFalk, Ferring, Janssen, Medical Research Future Fund, Pfizer, South Western Sydney Local Health District, Sydney Partnership for Health, Research and Enterprise, Takeda and The Leona M and Harry B Helmsley Charitable Trust Personal Fees: Ad Boards: Abbvie, Amgen, BMS, Celltrion, Eli Lilly, Ferring, GSK, Janssen, Organon, Pfizer, Takeda Speaker Fees: Abbvie, Cornerstones Health, Dr Falk, Ferring, Janssen, Pfizer, Sandoz, Sydney IBD School, Takeda Educational Support: DrFalk, Sandoz, Takeda Andrews, Jane Mary: Grant: The work I will present was funded via CCCure. CCCure’s funding sources include grants for research and payments for data reports from Pharma including AbbVie, J&J, Takeda, Celltrion, Falk, Ferring, BMS, Janssen, Pfizer, Sandoz